Institute Of Cancer Research Royal Cancer Hospital The and CANCER RESEARCH TECHNOLOGY Ltd | Date: 2015-09-14
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.
CANCER RESEARCH TECHNOLOGY Ltd and Institute Of Cancer Research Royal Cancer Hospital The | Date: 2015-07-30
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as IP compounds), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (mutant RAS cancer). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.
Cancer Research Technology Ltd | Date: 2014-11-12
The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.
Cancer Research Technology Ltd | Date: 2015-05-13
The invention relates to materials and methods for modifying the binding of antibodies, and more particularly to antibodies that are obtainable by inserting an amino acid sequence capable of binding to a target into a complementarity determining region of a parent antibody so that the antibody thus obtained is capable of binding to the target. The invention further relates to the uses of the antibodies for therapy, diagnosis or imaging, and to methods of producing the antibodies.
CANCER RESEARCH TECHNOLOGY Ltd | Date: 2014-12-11
AV6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AV6 mediated diseases.